Novartis Ag

Novartis Pharma Gmbh

Thomas Jung

Hermann Gram

Timothy Wright

Trevor Mundel

Phil Lowe

Philip Lowe

This invention relates to a novel use of IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Methods of treating a crystal induced arthropathy using IL-1beta antibodies

This invention relates to a novel use of IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1 beta Compounds'); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Method of treating auto-inflammatory syndromes with IL-1beta antibodies related to canakinumab

This invention relates to methods employing IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds such as IL-1&#x3b2; antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of Familial Mediterranean Fever (FMF), in mammals, particularly humans.

Methods of using IL-1&#x3b2; compounds to treat familial mediterranean fever (FMF)

Methods of treating Kawasaki disease using IL-1beta antibodies

This invention relates to a novel use of IL-1&#x25a1;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x25a1; ligand&#x2014;IL-1 receptor interaction, IL-1&#x25a1; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x25a1; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x25a1; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x25a1; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Methods of treating vascular disease using an IL-1beta Antibody

This invention relates to a novel use of IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x3b2; ligand-IL-1 receptor interaction, IL-1&#x3b2; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x3b2; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x3b2; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x3b2; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Methods of treating gout using IL-1BETA antibodies

This invention relates to methods employing IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x3b2; ligand-IL-1 receptor interaction, IL-1&#x3b2; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x3b2; binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x3b2; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x3b2; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Growing community of inventors

Vienna, Austria

Thomas Jung